Denosumab, an immune-modulating drug and a human monoclonal antibody against Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL) was effective in alleviating the dinitrobenzene sulfonic acid-induced colitis by immune activation and modulation of gut microbiome composition [60]. The gene discussed is TNFSF11; the disease is colitis.